Cite
HARVARD Citation
Chow, S. et al. (2016). High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. Journal for immunotherapy of cancer. 4 (1), p. . [Online].